Empagliflozin, Brand Name : Jardiance Kilogram

Niksan Pharmaceutical is one of the biggest manufacturer, supplier, exporter and trader of the EMPAGLIFLOZIN finished formulations moreover EMPAGLIFLOZINAPI. Niksan Pharmaceutical is the huge manufacturer, exporter and supplier of EMPAGLIFLOZINAPI and formulation situated in Ankleshwar, Gujarat, India.

Niksan Pharmaceutical is the suppliers, manufacturer, exporters and trader of
EMPAGLIFLOZIN inthe domestic level as well as the international market.

Niksan is an Indian based pharmaceutical company so it also supplies and manufactures the EMPAGLIFLOZIN to all Indian states like Gujarat, Maharashtra, Punjab, Delhi, Tamilnadu, Goa, Uttar Pradesh, Karnataka, Jammu & Kashmir, West Bengal, Assam, Rajasthan, Hyderabad, Karnataka, Kerala, Madhya Pradesh, Manipur, Meghalaya, Mizoram, Nagaland, Orissa, Punjab and Haryana.  

Niksan Pharmaceutical and Niksan group companies are exporters, suppliers and manufacturers of the API and also EMPAGLIFLOZIN formulations in many countries for many years. Niksan pharmaceutical currently exports EMPAGLIFLOZINAPI and Formulation to countries like New Zealand, Jordan, Belgium, United Kingdom, Australia, Italy, Ireland, Hong Kong, Morocco, Portugal, France, South Africa, Philippines, Malaysia, Singapore, Israel, Greece, Saudi Arabia, Egypt, Taiwan, Netherlands, South Korea, Switzerland, Algeria, Pakistan, Canada, Vietnam, United States, Germany, Brazil and many other countries.

EMPAGLIFLOZIN is an oral antihyperglycemic agent of the SGLT2 (sodium-glucose co-transporter 2) inhibitor class, used to improve glycemic control in adults with type 2 diabetes mellitus. It also reduces the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease.

SYNONYSMS:Jardiance

IUPAC NAME: (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-D-glucitol

CAS NO:864070-44-0

FORMULA:C23H27ClO7

MOLECULAR MASS:  450.91 g/mol

STORAGE CONDITIONS:Store at 20°C to 25°C (68°F to 77°F). Protect from moisture and light. Store in a tightly closed container in a cool, dry place.

HOW TO USE:The usual starting dose is 10 mg orally once daily in the morning, with or without food. Based on tolerance and clinical response, the dose may be increased to 25 mg once daily. Always use as prescribed by the physician.

HOW EMPAGLIFLOZIN WORKS: Empagliflozin works by inhibiting SGLT2 in the proximal renal tubules. This reduces glucose reabsorption and increases urinary glucose excretion, thereby lowering blood glucose levels. It also has beneficial effects on blood pressure and weight.

PHARMACOKINETICS OF EMPAGLIFLOZIN:Empagliflozin is rapidly absorbed after oral administration, with peak plasma concentrations occurring at 1.5 hours. It is 86% protein-bound, metabolized mainly by glucuronidation, and excreted via urine and feces. Terminal half-life is approximately 12.4 hours.

SIDE EFFECTS OF EMPAGLIFLOZIN:Urinary tract infections, Increased urination, Genital yeast infections, Dehydration, Hypotension, Increased cholesterol levels, Risk of ketoacidosis (rare), Acute kidney injury (rare)

PRECAUTIONS: Not for use in patients with type 1 diabetes or diabetic ketoacidosis. Monitor renal function before and during treatment. Use cautiously in patients on diuretics, those with low blood pressure, or history of urinary tract infections. Avoid in pregnancy unless necessary.

CDSCO APPROVAL: Emphagliflozin Tablet 10/25 mg
07.05.15

FORMULATIONS AVAILABLE IN MARKET:

EMPAGLIFLOZIN 10 MG Tablets

EMPAGLIFLOZIN 25 MG Tablets

EMPAGLIFLOZIN + METFORMIN Tablets

EMPAGLIFLOZIN + LINAGLIPTIN Tablets

Note: Product protected by valid patents are not offered for sale in countries where such patents are still valid and its liability is at Buyers Risk